Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study.

MLA

Marconcini, Riccardo, et al. “Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study.” Frontiers in Oncology, vol. 12, Aug. 2022, p. 917999. EBSCOhost, https://doi.org/10.3389/fonc.2022.917999.

APA

Marconcini, R., Fava, P., Nuzzo, A., Manacorda, S., Ferrari, M., De Rosa, F., De Tursi, M., Tanda, E. T., Consoli, F., Minisini, A., Pimpinelli, N., Morgese, F., Bersanelli, M., Tucci, M., Saponara, M., Parisi, A., Ocelli, M., Bazzurri, S., Massaro, G., … Stanganelli, I. (2022). Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study. Frontiers in Oncology, 12, 917999. https://doi.org/10.3389/fonc.2022.917999

Chicago

Marconcini, Riccardo, Paolo Fava, Amedeo Nuzzo, Simona Manacorda, Marco Ferrari, Francesco De Rosa, Michele De Tursi, et al. 2022. “Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study.” Frontiers in Oncology 12 (August): 917999. doi:10.3389/fonc.2022.917999.